Expertise in
3
conditions

Dr. Mohammad R. Bolouri

Neurology
Office
7809 Sardis Rd, 
Charlotte, NC 
Accepting New Patients
Expertise in
3
conditions
Office
7809 Sardis Rd, 
Charlotte, NC 

Overview

Mohammad Bolouri is a Neurologist practicing medicine in Charlotte, North Carolina.

Dr. Bolouri is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Cerebellar Degeneration, Alzheimer's Disease, Dementia, and Lewy Body Dementia (LBD).

He is actively involved in clinical research, participating in 12 clinical trials. Dr. Bolouri is currently accepting new patients.

Specialties

Neurology

Licenses

Psychiatry & Neurology in NC

Hospital Affiliations

Atrium Health Union
Novant Health Matthews Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Office
7809 Sardis Rd, Charlotte, NC 28270

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: November 10, 2025
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2025
Intervention Type: Drug
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Drug
Study Drug: CT1812
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease
A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drug: BPN14770
Study Phase: Phase 2
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials
Similar Doctors
Expertise in
11
conditions
Dr. Leo F. Mccluskey
Neurology | Neuromusculoskeletal Medicine
Expertise in
11
conditions
Dr. Leo F. Mccluskey
Neurology | Neuromusculoskeletal Medicine
Referral required
Before you request

Atrium Health Neurology Specialty Care, A Facility Of Carolinas Medical Center

1010 Edgehill Road N., 
Charlotte, NC 
 (5.3 miles away)
704-468-0101
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Leo Mccluskey is a Neurologist and a Neuromusculoskeletal Medicine provider practicing medicine in Charlotte, North Carolina. Dr. Mccluskey is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), and Spinal and Bulbar Muscular Atrophy. Dr. Mccluskey is board certified in American Board Of Psychiatry And Neurology, Neuromuscular Medicine and American Board Of Electrodiagnostic Medicine. Dr. Mccluskey is currently accepting new patients.

Expertise in
19
conditions
Expertise in
19
conditions
Referral required
Before you request

Atrium Health Neurology Specialty Care, A Facility Of Carolinas Medical Center

1010 Edgehill Road N., 
Charlotte, NC 
 (5.3 miles away)
704-468-0101
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Danielle Doggett is a Neurologist practicing medicine in Charlotte, North Carolina. Dr. Doggett is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Parkinson's Disease, Movement Disorders, Essential Tremor, Drug Induced Dyskinesia, and Deep Brain Stimulation. Dr. Doggett is board certified in American Board Of Psychiatry And Neurology. Dr. Doggett is currently accepting new patients.

Expertise in
32
conditions
Dr. Scott D. Wait
Neurology | General Surgery
Expertise in
32
conditions
Dr. Scott D. Wait
Neurology | General Surgery
Referral required
Before you request

Carolina Neurosurgery & Spine Associates - Charlotte

225 Baldwin Ave., 
Charlotte, NC 
 (6.4 miles away)
704-376-1605
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Wait is a Neurologist and a General Surgeon practicing medicine in Charlotte, North Carolina. Dr. Wait is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), Dysembryoplastic Neuroepithelial Tumors (DNET), Posterior Fossa Decompression, and Awake Craniotomy. Dr. Wait is board certified in American Board Of Neurological Surgery. Dr. Wait is currently accepting new patients.

Frequently Asked Questions about Dr. Mohammad R. Bolouri

How do I make an appointment with Dr. Mohammad R. Bolouri?

You can book an appointment with Dr. Mohammad R. Bolouri by calling their office at 704-364-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mohammad R. Bolouri a top-rated expert for Cerebellar Degeneration?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mohammad R. Bolouri is classified as an Distinguished expert for Cerebellar Degeneration, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mohammad R. Bolouri specialize in?

While Dr. Mohammad R. Bolouri is a Neurology, they have specific expertise in Cerebellar Degeneration, Alzheimer's Disease, and Dementia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Mohammad R. Bolouri accept my insurance?

Dr. Mohammad R. Bolouri accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 704-364-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bolouri's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile